Computational Medicine and Drug Discovery Software Market Size Forecast to Reach $965.27 Million by 2025

The Computational Medicine and Drug Discovery Software Market size are forecast to reach $965.27 million by 2025, growing at a CAGR of 4.6% during the forecast period 2020-2025. Computational Medicine involves a combination of mathematics, engineering, and computer science. It is an emerging field that is devoted to developing for understanding the mechanisms, diagnosis, and treatment of human disease. The emerging trend of consuming personalized medicine and the advancement of information technology along with the advent of the fast and accurate computational platform has considerably reduced the time taken for drug discovery & development and are the major factors driving the growth of the market. Rising bioinformatics in drug discovery is set to further enhance the overall market demand for the Computational Medicine and Drug Discovery Software Market during the forecast period 2020-2025.

Key Takeaways
North America dominated the Computational Medicine and Drug Discovery Software Market in 2019 owing to the highest demand with the advancement in pharmaceutical industries. The Computational Medicine and Drug Discovery Software Market scope for different regions will be provided in the final report.
The increasing evolution of dimensional drug discovery methodology and increasing research activities on drug designing and development is likely to aid in the market growth of the Computational Medicine and Drug Discovery Software Market.
Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Computational Medicine and Drug Discovery Software Market report.
Lack of skilled resources to operate computational tools is set to create hurdles for the Computational Medicine and Drug Discovery Software Market.

Applications- Segment Analysis
The Drug Discovery & Development segment held the largest share in the Computational Medicine and Drug Discovery Software Market in 2019 and is estimated to grow at a CAGR of 5.2% during the forecast period 2020-2025. New medications are discovered by the drug discovery process. Classical pharmacology is used to investigate chemical libraries including small molecules, natural products, or plant extract. Since human DNA was sequenced, reverse pharmacology has found remedies to existing diseases through testing. Disease processes, molecular compound tests, existing treatments with unanticipated effects, and new technologies spur drug discovery. Drug discovery & development involves screening hits, medicinal chemistry, and optimization of hits to reduce potential drug side effects by increasing affinity and selectivity. In drug discovery & development, target identification finds a gene or protein that plays a significant role in disease. When identified, therapeutic characteristics are recorded. Targets are efficacious, safe, usable as drugs, and capable of meeting clinical and commercial requirements. Researchers use disease association, bioactive molecules, cell-based models, protein interactions, signalling pathways analysis, and functional analysis of genes to validate targets. Drug discovery and development is not only a time-consuming and labour-intensive process but also full of risk. Identifying targets of small molecules help evaluate the safety of drugs and find new therapeutic applications. Biotechnology measures a wide variety of properties related to drugs and targets from different perspectives, thus generating a large body of data. Proteomics is the large-scale study of proteins. Proteins are vital parts of living organisms, with many functions. The proteome is the entire set of proteins that are produced or modified by an organism or system and has enabled the identification of ever-increasing numbers of protein. The Drug Discovery & Development is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.

Geography – Segment Analysis
North America dominated the Computational Medicine and Drug Discovery Software Market in 2019 with a share of 49.86%. This is owing to the highest demand with the advancement in pharmaceutical industries. Rising demand for personalized medicines, usefulness in drug development & increased investment in research and development is set to increase the computational medicine and drug discovery software market in this region.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the growing adoption of technological innovations in the field of medicine.The rising use of computational tools in genomics and metagenomics to understand 3D protein structural analysis is also increasing the growth of the computational medicine and drug discovery software market in this region.

Drivers – Computational Medicine and Drug Discovery Software Market
The emerging trend of consuming personalized medicine and the advancement of information technology along with the advent of fast and accurate computational platform
The emerging trend of consuming personalized medicine and the advancement of information technology along with the advent of the fast and accurate computational platforms is increasing the growth of the computational medicine and drug discovery software market. Healthcare is transforming, and it is imperative to leverage new technologies to generate new data and support the advent of precision medicine. Deep clinical phenotyping, combined with advanced molecular phenotypic profiling, enables the construction of causal network models in which a genomic region is proposed to influence the levels of transcripts, proteins, and metabolites. Phenotypic analysis bears great importance to elucidate the pathophysiology of networks at the molecular and cellular level. Digital biomarkers (BMs) can have several applications beyond clinical trials in diagnostics—to identify patients affected by a disease or to guide treatment. In Computational medicine and drug discovery software, information technologies enhance the chemical structure prediction, heterogeneous database access, pattern discovery, and systems & molecular modeling that have evolved to become core components of the modern computational medicine and drug discovery software. With increasing productivity, information technology has helped pharmaceutical companies to reduce the high failure rate in the drug discovery process and the high cost of the various phase of clinical trials acts as limiting factors for several drugs, which can be developed by pharmaceutical companies and hence information technology helps in selecting the compounds with the best chances for approval. Thus, increasing the growth of the computational medicine and drug discovery software market during the forecast period 2020-2025.

Increasing evolution of dimensional drug discovery methodology and increasing research activities on drug designing and development
The increasing evolution of dimensional drug discovery methodology and increasing research activities on drug designing and development is increasing the growth of the computational medicine and drug discovery software market. Pharmaceutical companies are increasingly outsourcing research activities to academic and private contract research organizations (CROs) as a strategy to stay competitive and flexible in a world of exponentially growing knowledge, increasingly sophisticated technologies on drug discovery & development. Recent advances in computational medicine and powerful tools to enhance computational capacity are enabling researchers to better understand the inner workings of human disease at the molecular level. Advancements in science and technology are changing the way we define disease, develop drugs, and prescribe treatments. Armed with a greater understanding of disease biology, it has become evident that a patient’s response to treatment— concerning both safety and efficacy—is greatly dependent upon his or her molecular profile and genetic makeup. Thus, increasing the growth of the computational medicine and drug discovery software market during the forecast period 2020-2025.

Challenges – Computational Medicine and Drug Discovery Software Market
Lack of skilled resources to operate computational tools
Some of the factors that can impede the growth of the Computational Medicine and Drug Discovery Software Market are lack of skilled resources to operate computational tools

Computational Medicine and Drug Discovery Software Market Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Computational Medicine and Drug Discovery Software Market. In 2019, the Computational Medicine and Drug Discovery Software Market share are consolidated by the top ten players present in the market. Computational Medicine and Drug Discovery Software Market, the top 10 companies are Dassault Systemes, Scrodinger LLC, Genedata LLC, Entelos Inc., Nimbus Therapeutics Inc., Chemical Computing Group, Instem PLC, Crown Biosciences Inc., Roche, and Certara LP among others.

Acquisitions/Product Launches
In February 2018, Roche acquired oncology tech company Flatiron Health to implement the use of artificial intelligence as another tool to facilitate drug discovery and help the company progress. This acquisition with Flatiron Health provided the required technology and data analytics needed for Roche as well as oncology research and development across the industry.